# Pamrevlumab

Source: https://onco.cc/drugs/pamrevlumab/  
OnCo record `pamrevlumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pamrevlumab targeted the scar-like tissue around pancreatic tumours; its phase 3 LAPIS trial in locally advanced disease did not lengthen survival.

## Summary

FibroGen developed pamrevlumab for fibrotic diseases and for pancreatic cancer, where connective tissue growth factor helps build the stroma that shields tumour cells. A phase 1/2 study suggested more patients could reach surgery.

The phase 3 LAPIS trial in locally advanced unresectable pancreatic cancer, combined with gemcitabine and nab-paclitaxel or FOLFIRINOX, did not meet its overall survival endpoint, reported in 2024. A metastatic arm within the Precision Promise platform trial was also stopped for futility, ending the programme.

## Fields

- Kind: Treatment
- Status: negative
- Last checked: 2026-09-17
- Also known as: FG-3019
- Code: FG-3019
- Modality: Monoclonal antibody against connective tissue growth factor (CTGF)
- Mechanism: Binds connective tissue growth factor, a driver of the dense fibrous stroma that surrounds pancreatic tumours, aiming to make them more resectable and more permeable to chemotherapy.

## Sources

- ClinicalTrials.gov NCT03941093: https://clinicaltrials.gov/study/NCT03941093
- FibroGen announcement, LAPIS topline results (2024): https://investor.fibrogen.com/news-releases

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- companies: [FibroGen](https://onco.cc/companies/fibrogen/)
- trials: [LAPIS](https://onco.cc/trials/lapis-trial/), [Precision Promise](https://onco.cc/trials/precision-promise/)

---
JSON: https://onco.cc/api/v1/entities/pamrevlumab.json